Details
Stereochemistry | ACHIRAL |
Molecular Formula | C8H15N7O2S3 |
Molecular Weight | 337.445 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
NC(=N)NC1=NC(CSCCC(=N)NS(N)(=O)=O)=CS1
InChI
InChIKey=XUFQPHANEAPEMJ-UHFFFAOYSA-N
InChI=1S/C8H15N7O2S3/c9-6(15-20(12,16)17)1-2-18-3-5-4-19-8(13-5)14-7(10)11/h4H,1-3H2,(H2,9,15)(H2,12,16,17)(H4,10,11,13,14)
DescriptionSources: http://www.drugbank.ca/drugs/DB00927Curator's Comment: Description was created based on several sources, including
https://www.drugs.com/famotidine.html
Sources: http://www.drugbank.ca/drugs/DB00927
Curator's Comment: Description was created based on several sources, including
https://www.drugs.com/famotidine.html
Famotidine, a competitive histamine H2-receptor antagonist, is used to treat gastrointestinal disorders such as gastric or duodenal ulcer, gastroesophageal reflux disease, and pathological hypersecretory conditions. Famotidine inhibits many of the isoenzymes of the hepatic CYP450 enzyme system. Other actions of Famotidine include an increase in gastric bacterial flora such as nitrate-reducing organisms. Famotidine binds competitively to H2-receptors located on the basolateral membrane of the parietal cell, blocking histamine affects. This competitive inhibition results in reduced basal and nocturnal gastric acid secretion and a reduction in gastric volume, acidity, and amount of gastric acid released in response to stimuli including food, caffeine, insulin, betazole, or pentagastrin.
CNS Activity
Sources: https://www.ncbi.nlm.nih.gov/pubmed/8204567
Curator's Comment: Famotidine is a potent highly selective H2 receptor antagonist which crosses the blood-brain barrier.
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL1941 Sources: http://www.drugbank.ca/drugs/DB00927 |
0.3 µM [IC50] | ||
Target ID: CHEMBL2073673 Sources: https://www.ncbi.nlm.nih.gov/pubmed/16141367 |
6.7 µM [IC50] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Curative | PEPCID Approved UsePEPCID is indicated in:
1. Short-term treatment of active duodenal ulcer.
2. Maintenance therapy for duodenal ulcer patients at reduced dosage after healing of an active ulcer.
3. Short-term treatment of active benign gastric ulcer.
4. Short-term treatment of gastroesophageal reflux disease (GERD). PEPCID is indicated for shortterm
treatment of patients with symptoms of GERD
PEPCID is also indicated for the short-term treatment of esophagitis due to GERD including erosive or ulcerative disease diagnosed by endoscopy
5. Treatment of pathological hypersecretory conditions (e.g., Zollinger-Ellison Syndrome, multiple
endocrine adenomas) Launch Date1986 |
|||
Curative | PEPCID Approved UsePEPCID is indicated in:
1. Short-term treatment of active duodenal ulcer.
2. Maintenance therapy for duodenal ulcer patients at reduced dosage after healing of an active ulcer.
3. Short-term treatment of active benign gastric ulcer.
4. Short-term treatment of gastroesophageal reflux disease (GERD). PEPCID is indicated for shortterm
treatment of patients with symptoms of GERD
PEPCID is also indicated for the short-term treatment of esophagitis due to GERD including erosive or ulcerative disease diagnosed by endoscopy
5. Treatment of pathological hypersecretory conditions (e.g., Zollinger-Ellison Syndrome, multiple
endocrine adenomas) Launch Date1986 |
|||
Primary | PEPCID Approved UsePEPCID is indicated in:
1. Short-term treatment of active duodenal ulcer.
2. Maintenance therapy for duodenal ulcer patients at reduced dosage after healing of an active ulcer.
3. Short-term treatment of active benign gastric ulcer.
4. Short-term treatment of gastroesophageal reflux disease (GERD). PEPCID is indicated for shortterm
treatment of patients with symptoms of GERD
PEPCID is also indicated for the short-term treatment of esophagitis due to GERD including erosive or ulcerative disease diagnosed by endoscopy
5. Treatment of pathological hypersecretory conditions (e.g., Zollinger-Ellison Syndrome, multiple
endocrine adenomas) Launch Date1986 |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
73 ng/mL |
20 mg single, oral dose: 20 mg route of administration: Oral experiment type: SINGLE co-administered: |
FAMOTIDINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
424 ng × h/mL |
20 mg single, oral dose: 20 mg route of administration: Oral experiment type: SINGLE co-administered: |
FAMOTIDINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
3 h |
20 mg single, oral dose: 20 mg route of administration: Oral experiment type: SINGLE co-administered: |
FAMOTIDINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
Funbound
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
82.5% |
20 mg single, oral dose: 20 mg route of administration: Oral experiment type: SINGLE co-administered: |
FAMOTIDINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
Doses
Dose | Population | Adverse events |
---|---|---|
0.5 mg/kg 2 times / day steady, oral Recommended Dose: 0.5 mg/kg, 2 times / day Route: oral Route: steady Dose: 0.5 mg/kg, 2 times / day Sources: |
unhealthy, 11 - 15 years n = 8 Health Status: unhealthy Condition: gastric or duodenal ulcers Age Group: 11 - 15 years Sex: M Population Size: 8 Sources: |
|
80 mg 3 times / day steady, oral Highest studied dose Dose: 80 mg, 3 times / day Route: oral Route: steady Dose: 80 mg, 3 times / day Sources: |
unhealthy, 20 - 70 years n = 10 Health Status: unhealthy Condition: COVID-19 Age Group: 20 - 70 years Sex: M+F Population Size: 10 Sources: |
Other AEs: Dizziness, Dry skin... Other AEs: Dizziness (grade 1, 2 patients) Sources: Dry skin (grade 1, 1 patient) Insomnia (grade 1, 1 patient) Gastrointestinal disorder (NOS) (grade 1, 1 patient) Forgetfulness (grade 1, 1 patient) |
1 mg/kg 1 times / day steady, intravenous Recommended Dose: 1 mg/kg, 1 times / day Route: intravenous Route: steady Dose: 1 mg/kg, 1 times / day Sources: |
unhealthy, 6 - 15 years n = 6 Health Status: unhealthy Condition: gastric or duodenal ulcers Age Group: 6 - 15 years Sex: M Population Size: 6 Sources: |
|
26.6 mg 3 times / day steady, oral Highest studied dose Dose: 26.6 mg, 3 times / day Route: oral Route: steady Dose: 26.6 mg, 3 times / day Co-administed with:: ibuprofen(800 mg) Sources: |
unhealthy, adult n = 1022 Health Status: unhealthy Condition: chronic pain and inflammation of stomach Age Group: adult Sex: M+F Population Size: 1022 Sources: |
Other AEs: Anemia, Nausea... Other AEs: Anemia (2 patients) Sources: Nausea (6 patients) Dyspepsia (5 patients) Diarrhea (5 patients) Constipation (4 patients) Abdominal pain upper (3 patients) Gastroesophageal reflux disease (2 patients) Vomiting (2 patients) Stomach discomfort (2 patients) Abdominal pain (2 patients) Edema peripheral (2 patients) Arthralgia (1 patient) Back pain (2 patients) Headache (3 patients) Hypertension (3 patients) |
AEs
AE | Significance | Dose | Population |
---|---|---|---|
Dry skin | grade 1, 1 patient | 80 mg 3 times / day steady, oral Highest studied dose Dose: 80 mg, 3 times / day Route: oral Route: steady Dose: 80 mg, 3 times / day Sources: |
unhealthy, 20 - 70 years n = 10 Health Status: unhealthy Condition: COVID-19 Age Group: 20 - 70 years Sex: M+F Population Size: 10 Sources: |
Forgetfulness | grade 1, 1 patient | 80 mg 3 times / day steady, oral Highest studied dose Dose: 80 mg, 3 times / day Route: oral Route: steady Dose: 80 mg, 3 times / day Sources: |
unhealthy, 20 - 70 years n = 10 Health Status: unhealthy Condition: COVID-19 Age Group: 20 - 70 years Sex: M+F Population Size: 10 Sources: |
Gastrointestinal disorder (NOS) | grade 1, 1 patient | 80 mg 3 times / day steady, oral Highest studied dose Dose: 80 mg, 3 times / day Route: oral Route: steady Dose: 80 mg, 3 times / day Sources: |
unhealthy, 20 - 70 years n = 10 Health Status: unhealthy Condition: COVID-19 Age Group: 20 - 70 years Sex: M+F Population Size: 10 Sources: |
Insomnia | grade 1, 1 patient | 80 mg 3 times / day steady, oral Highest studied dose Dose: 80 mg, 3 times / day Route: oral Route: steady Dose: 80 mg, 3 times / day Sources: |
unhealthy, 20 - 70 years n = 10 Health Status: unhealthy Condition: COVID-19 Age Group: 20 - 70 years Sex: M+F Population Size: 10 Sources: |
Dizziness | grade 1, 2 patients | 80 mg 3 times / day steady, oral Highest studied dose Dose: 80 mg, 3 times / day Route: oral Route: steady Dose: 80 mg, 3 times / day Sources: |
unhealthy, 20 - 70 years n = 10 Health Status: unhealthy Condition: COVID-19 Age Group: 20 - 70 years Sex: M+F Population Size: 10 Sources: |
Arthralgia | 1 patient | 26.6 mg 3 times / day steady, oral Highest studied dose Dose: 26.6 mg, 3 times / day Route: oral Route: steady Dose: 26.6 mg, 3 times / day Co-administed with:: ibuprofen(800 mg) Sources: |
unhealthy, adult n = 1022 Health Status: unhealthy Condition: chronic pain and inflammation of stomach Age Group: adult Sex: M+F Population Size: 1022 Sources: |
Abdominal pain | 2 patients | 26.6 mg 3 times / day steady, oral Highest studied dose Dose: 26.6 mg, 3 times / day Route: oral Route: steady Dose: 26.6 mg, 3 times / day Co-administed with:: ibuprofen(800 mg) Sources: |
unhealthy, adult n = 1022 Health Status: unhealthy Condition: chronic pain and inflammation of stomach Age Group: adult Sex: M+F Population Size: 1022 Sources: |
Anemia | 2 patients | 26.6 mg 3 times / day steady, oral Highest studied dose Dose: 26.6 mg, 3 times / day Route: oral Route: steady Dose: 26.6 mg, 3 times / day Co-administed with:: ibuprofen(800 mg) Sources: |
unhealthy, adult n = 1022 Health Status: unhealthy Condition: chronic pain and inflammation of stomach Age Group: adult Sex: M+F Population Size: 1022 Sources: |
Back pain | 2 patients | 26.6 mg 3 times / day steady, oral Highest studied dose Dose: 26.6 mg, 3 times / day Route: oral Route: steady Dose: 26.6 mg, 3 times / day Co-administed with:: ibuprofen(800 mg) Sources: |
unhealthy, adult n = 1022 Health Status: unhealthy Condition: chronic pain and inflammation of stomach Age Group: adult Sex: M+F Population Size: 1022 Sources: |
Edema peripheral | 2 patients | 26.6 mg 3 times / day steady, oral Highest studied dose Dose: 26.6 mg, 3 times / day Route: oral Route: steady Dose: 26.6 mg, 3 times / day Co-administed with:: ibuprofen(800 mg) Sources: |
unhealthy, adult n = 1022 Health Status: unhealthy Condition: chronic pain and inflammation of stomach Age Group: adult Sex: M+F Population Size: 1022 Sources: |
Gastroesophageal reflux disease | 2 patients | 26.6 mg 3 times / day steady, oral Highest studied dose Dose: 26.6 mg, 3 times / day Route: oral Route: steady Dose: 26.6 mg, 3 times / day Co-administed with:: ibuprofen(800 mg) Sources: |
unhealthy, adult n = 1022 Health Status: unhealthy Condition: chronic pain and inflammation of stomach Age Group: adult Sex: M+F Population Size: 1022 Sources: |
Stomach discomfort | 2 patients | 26.6 mg 3 times / day steady, oral Highest studied dose Dose: 26.6 mg, 3 times / day Route: oral Route: steady Dose: 26.6 mg, 3 times / day Co-administed with:: ibuprofen(800 mg) Sources: |
unhealthy, adult n = 1022 Health Status: unhealthy Condition: chronic pain and inflammation of stomach Age Group: adult Sex: M+F Population Size: 1022 Sources: |
Vomiting | 2 patients | 26.6 mg 3 times / day steady, oral Highest studied dose Dose: 26.6 mg, 3 times / day Route: oral Route: steady Dose: 26.6 mg, 3 times / day Co-administed with:: ibuprofen(800 mg) Sources: |
unhealthy, adult n = 1022 Health Status: unhealthy Condition: chronic pain and inflammation of stomach Age Group: adult Sex: M+F Population Size: 1022 Sources: |
Abdominal pain upper | 3 patients | 26.6 mg 3 times / day steady, oral Highest studied dose Dose: 26.6 mg, 3 times / day Route: oral Route: steady Dose: 26.6 mg, 3 times / day Co-administed with:: ibuprofen(800 mg) Sources: |
unhealthy, adult n = 1022 Health Status: unhealthy Condition: chronic pain and inflammation of stomach Age Group: adult Sex: M+F Population Size: 1022 Sources: |
Headache | 3 patients | 26.6 mg 3 times / day steady, oral Highest studied dose Dose: 26.6 mg, 3 times / day Route: oral Route: steady Dose: 26.6 mg, 3 times / day Co-administed with:: ibuprofen(800 mg) Sources: |
unhealthy, adult n = 1022 Health Status: unhealthy Condition: chronic pain and inflammation of stomach Age Group: adult Sex: M+F Population Size: 1022 Sources: |
Hypertension | 3 patients | 26.6 mg 3 times / day steady, oral Highest studied dose Dose: 26.6 mg, 3 times / day Route: oral Route: steady Dose: 26.6 mg, 3 times / day Co-administed with:: ibuprofen(800 mg) Sources: |
unhealthy, adult n = 1022 Health Status: unhealthy Condition: chronic pain and inflammation of stomach Age Group: adult Sex: M+F Population Size: 1022 Sources: |
Constipation | 4 patients | 26.6 mg 3 times / day steady, oral Highest studied dose Dose: 26.6 mg, 3 times / day Route: oral Route: steady Dose: 26.6 mg, 3 times / day Co-administed with:: ibuprofen(800 mg) Sources: |
unhealthy, adult n = 1022 Health Status: unhealthy Condition: chronic pain and inflammation of stomach Age Group: adult Sex: M+F Population Size: 1022 Sources: |
Diarrhea | 5 patients | 26.6 mg 3 times / day steady, oral Highest studied dose Dose: 26.6 mg, 3 times / day Route: oral Route: steady Dose: 26.6 mg, 3 times / day Co-administed with:: ibuprofen(800 mg) Sources: |
unhealthy, adult n = 1022 Health Status: unhealthy Condition: chronic pain and inflammation of stomach Age Group: adult Sex: M+F Population Size: 1022 Sources: |
Dyspepsia | 5 patients | 26.6 mg 3 times / day steady, oral Highest studied dose Dose: 26.6 mg, 3 times / day Route: oral Route: steady Dose: 26.6 mg, 3 times / day Co-administed with:: ibuprofen(800 mg) Sources: |
unhealthy, adult n = 1022 Health Status: unhealthy Condition: chronic pain and inflammation of stomach Age Group: adult Sex: M+F Population Size: 1022 Sources: |
Nausea | 6 patients | 26.6 mg 3 times / day steady, oral Highest studied dose Dose: 26.6 mg, 3 times / day Route: oral Route: steady Dose: 26.6 mg, 3 times / day Co-administed with:: ibuprofen(800 mg) Sources: |
unhealthy, adult n = 1022 Health Status: unhealthy Condition: chronic pain and inflammation of stomach Age Group: adult Sex: M+F Population Size: 1022 Sources: |
Overview
CYP3A4 | CYP2C9 | CYP2D6 | hERG |
---|---|---|---|
OverviewOther
Other Inhibitor | Other Substrate | Other Inducer |
---|---|---|
Drug as perpetrator
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
Page: 6.0 |
weak | likely (co-administration study) Comment: may lead to substantial increases in blood concentrations of tizanidine, a CYP1A2 substrate; can't find inhibition value Page: 6.0 |
||
yes [IC50 114 uM] | ||||
yes [IC50 28 uM] | ||||
yes [IC50 6.7 uM] | ||||
Page: 1.0 |
yes [Inhibition 100 uM] | |||
Page: 1.0 |
yes [Inhibition 100 uM] | |||
Page: 1.0 |
yes [Inhibition 100 uM] | |||
yes [Ki 0.6 uM] | ||||
yes [Ki 9.7 uM] |
Drug as victim
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
yes |
Tox targets
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
PubMed
Title | Date | PubMed |
---|---|---|
Differences in the antisecretory actions of the proton pump inhibitor AG-1749 (lansoprazole) and the histamine H2-receptor antagonist famotidine in rats and dogs. | 1991 Apr |
|
The effect of rabeprazole alone or in combination with H2 receptor blocker on intragastric pH: a pilot study. | 2004 Dec |
|
Switching of H(2)-Receptor Antagonists to Over-the-Counter Status in Finland : Implications for Consumption and Adverse Effects. | 2005 |
|
[Gastroprotective effects of histamine H2-receptor blockers in Helicobacter-like gastric mucosa lesions]. | 2005 |
|
Differential substrate and inhibitory activities of ranitidine and famotidine toward human organic cation transporter 1 (hOCT1; SLC22A1), hOCT2 (SLC22A2), and hOCT3 (SLC22A3). | 2005 Dec |
|
Effect of preoperative short course famotidine on TILs and survival in breast cancer. | 2005 Oct-Dec |
|
[Complex evaluation of the action of inhibitors of hydrochloric acid secretion on gastric function in ulcer disease]. | 2006 |
|
Histamine mediates the stimulatory action of ghrelin on acid secretion in rat stomach. | 2006 Aug |
|
Cimetidine induces interleukin-18 production through H2-agonist activity in monocytes. | 2006 Aug |
|
Assessing the efficacy of famotidine and rebamipide in the treatment of gastric mucosal lesions in patients receiving long-term NSAID therapy (FORCE--famotidine or rebamipide in comparison by endoscopy). | 2006 Dec |
|
In vitro availability of metformin in presence of h(2) receptor antagonists. | 2006 Jan |
|
Activity of continuous infusion plus pulse interleukin-2 with famotidine in patients with metastatic kidney cancer or melanoma previously treated with interleukin-2. | 2006 Oct |
|
Tolerance to H2 receptor antagonist correlates well with the decline in efficacy against gastroesophageal reflux in patients with gastroesophageal reflux disease. | 2006 Oct |
|
Expression of HSP72 in the gastric mucosa is regulated by gastric acid in rats-correlation of HSP72 expression with mucosal protection. | 2006 Oct 20 |
|
Impact of blockade of histamine H2 receptors on chronic heart failure revealed by retrospective and prospective randomized studies. | 2006 Oct 3 |
|
Omeprazole may be superior to famotidine in the management of iatrogenic ulcer after endoscopic mucosal resection: a prospective randomized controlled trial. | 2006 Sep 1 |
|
Histamine stimulation of MMP-1(collagenase-1) secretion and gene expression in gastric epithelial cells: role of EGFR transactivation and the MAP kinase pathway. | 2007 |
|
The efficacy of hydrotalcite compared with OTC famotidine in the on-demand treatment of gastroesophageal reflux disease: a non-inferiority trial. | 2007 Jan |
|
[Clinical study on effect of Jianwei Yuyang Granule in treating patients with gastric ulcer]. | 2007 Jul |
|
Novel role of famotidine in downregulation of matrix metalloproteinase-9 during protection of ethanol-induced acute gastric ulcer. | 2007 Jul 15 |
|
The role of tumor necrosis factor alpha in lipopolysaccharide/ranitidine-induced inflammatory liver injury. | 2007 Nov |
|
Gastric antisecretory drugs induce leukocyte-endothelial cell interactions through gastrin release and activation of CCK-2 receptors. | 2007 Oct |
|
Gastroprotective and antioxidant effects of montelukast on indomethacin-induced gastric ulcer in rats. | 2007 Sep |
|
A randomized, double-blind, placebo-controlled clinical study of the histamine H2-receptor antagonist famotidine in Japanese patients with nonerosive reflux disease. | 2008 |
|
Can negative cardiac effect of proton pump inhibitor and high-dose H2-blocker have clinical influence on patients with stable angina? | 2008 Aug |
|
Low-dose cyclophosphamide and continuous-infusion interleukin-2 with famotidine in previously treated metastatic melanoma or kidney cancer. | 2008 Feb |
|
Antinociception induced by central administration of histamine in the formalin test in rats. | 2008 Jul-Sep |
|
Nonsurgical resolution of gallbladder mucocele in two dogs. | 2008 Jun 1 |
|
Effects of mepyramine and famotidine on the physostigmine-induced antinociception in the formalin test in rats. | 2008 Nov 15 |
|
High-dose intensity pulse interleukin-2 with famotidine has activity in metastatic melanoma. | 2008 Oct |
|
[Efficacy and safety of famotidine for the treatment of stress ulcers in neonates]. | 2008 Oct |
|
Gastroprotective and anti-oxidative properties of ascorbic acid on indomethacin-induced gastric injuries in rats. | 2008 Winter |
|
Risk factors for the development of gastric mucosal lesions in rheumatoid arthritis patients receiving long-term nonsteroidal anti-inflammatory drug therapy and the efficacy of famotidine obtained from the FORCE study. | 2009 |
|
Comparison of the effects of omeprazole and famotidine in treatment of upper abdominal symptoms in patients with reflux esophagitis. | 2009 |
|
Cytokine responses of intraepithelial lymphocytes are regulated by histamine H(2) receptor. | 2009 |
|
High-dose intensity pulse interleukin-2 with famotidine in metastatic kidney cancer. | 2009 Apr |
|
Phosphodiesterase isozymes involved in regulating acid secretion in the isolated mouse stomach. | 2009 Dec |
|
Activity of continuous infusion + pulse interleukin-2 with famotidine in metastatic melanoma. | 2009 Feb |
|
Hepatitis following famotidine: a case report. | 2009 Jan 27 |
|
Comparative study on the gastroprotective potential of some antidepressants in indomethacin-induced ulcer in rats. | 2009 Jul 15 |
|
Drug-induced torsades de pointes: data mining of the public version of the FDA Adverse Event Reporting System (AERS). | 2009 Jun |
|
Characterization of mechanisms underlying the effects of esomeprazole on the impairment of gastric ulcer healing with addition of NSAID treatment. | 2009 Jun |
|
Effects of pantoprazole on ulcer healing delay associated with NSAID treatment. | 2009 Mar |
|
[Neurological complications of acute intermittent porphyria precipitated by porphyrinogenic drugs and efficiency of heme-arginate treatment]. | 2009 Sep |
|
Protective effect of mirtazapine on indomethacin-induced ulcer in rats and its relationship with oxidant and antioxidant parameters. | 2009 Sep |
|
Pulse infusion interleukin-2 with famotidine and cyclophosphamide has activity in previously treated metastatic melanoma. | 2010 Apr |
|
Rebamipide may be comparable to H2 receptor antagonist in healing iatrogenic gastric ulcers created by endoscopic mucosal resection: a prospective randomized pilot study. | 2010 Apr |
|
Famotidine is inferior to pantoprazole in preventing recurrence of aspirin-related peptic ulcers or erosions. | 2010 Jan |
|
Effect of histamine H2 receptor antagonism on levodopa-induced dyskinesia in the MPTP-macaque model of Parkinson's disease. | 2010 Jul 30 |
|
Hepatoprotective, antinociceptive and antioxidant activities of cimetidine, ranitidine and famotidine as histamine H2 receptor antagonists. | 2011 Feb |
Patents
Sample Use Guides
The recommended adult oral dosage for active duodenal ulcer is 40 mg once a day at bedtime. Most patients heal within 4 weeks.
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/23857299
Famotidine (10-1,000 µM) inhibited methadone and oxycodone cytochrome P450-dependent metabolism >50%.
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Code | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Brand Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Code | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
WHO-ATC |
A02BA03
Created by
admin on Fri Dec 15 15:52:37 GMT 2023 , Edited by admin on Fri Dec 15 15:52:37 GMT 2023
|
||
|
NDF-RT |
N0000175784
Created by
admin on Fri Dec 15 15:52:37 GMT 2023 , Edited by admin on Fri Dec 15 15:52:37 GMT 2023
|
||
|
WHO-VATC |
QA02BA03
Created by
admin on Fri Dec 15 15:52:37 GMT 2023 , Edited by admin on Fri Dec 15 15:52:37 GMT 2023
|
||
|
NCI_THESAURUS |
C29702
Created by
admin on Fri Dec 15 15:52:37 GMT 2023 , Edited by admin on Fri Dec 15 15:52:37 GMT 2023
|
||
|
WHO-ATC |
A02BA53
Created by
admin on Fri Dec 15 15:52:37 GMT 2023 , Edited by admin on Fri Dec 15 15:52:37 GMT 2023
|
||
|
LIVERTOX |
NBK548228
Created by
admin on Fri Dec 15 15:52:37 GMT 2023 , Edited by admin on Fri Dec 15 15:52:37 GMT 2023
|
||
|
WHO-VATC |
QA02BA53
Created by
admin on Fri Dec 15 15:52:37 GMT 2023 , Edited by admin on Fri Dec 15 15:52:37 GMT 2023
|
||
|
NDF-RT |
N0000000151
Created by
admin on Fri Dec 15 15:52:37 GMT 2023 , Edited by admin on Fri Dec 15 15:52:37 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
Famotidine
Created by
admin on Fri Dec 15 15:52:37 GMT 2023 , Edited by admin on Fri Dec 15 15:52:37 GMT 2023
|
PRIMARY | |||
|
DTXSID5023039
Created by
admin on Fri Dec 15 15:52:37 GMT 2023 , Edited by admin on Fri Dec 15 15:52:37 GMT 2023
|
PRIMARY | |||
|
DB00927
Created by
admin on Fri Dec 15 15:52:37 GMT 2023 , Edited by admin on Fri Dec 15 15:52:37 GMT 2023
|
PRIMARY | |||
|
757810
Created by
admin on Fri Dec 15 15:52:37 GMT 2023 , Edited by admin on Fri Dec 15 15:52:37 GMT 2023
|
PRIMARY | |||
|
D015738
Created by
admin on Fri Dec 15 15:52:37 GMT 2023 , Edited by admin on Fri Dec 15 15:52:37 GMT 2023
|
PRIMARY | |||
|
SUB07503MIG
Created by
admin on Fri Dec 15 15:52:37 GMT 2023 , Edited by admin on Fri Dec 15 15:52:37 GMT 2023
|
PRIMARY | |||
|
5QZO15J2Z8
Created by
admin on Fri Dec 15 15:52:37 GMT 2023 , Edited by admin on Fri Dec 15 15:52:37 GMT 2023
|
PRIMARY | |||
|
5217
Created by
admin on Fri Dec 15 15:52:37 GMT 2023 , Edited by admin on Fri Dec 15 15:52:37 GMT 2023
|
PRIMARY | |||
|
100000092363
Created by
admin on Fri Dec 15 15:52:37 GMT 2023 , Edited by admin on Fri Dec 15 15:52:37 GMT 2023
|
PRIMARY | |||
|
7074
Created by
admin on Fri Dec 15 15:52:37 GMT 2023 , Edited by admin on Fri Dec 15 15:52:37 GMT 2023
|
PRIMARY | |||
|
3325
Created by
admin on Fri Dec 15 15:52:37 GMT 2023 , Edited by admin on Fri Dec 15 15:52:37 GMT 2023
|
PRIMARY | |||
|
m5241
Created by
admin on Fri Dec 15 15:52:37 GMT 2023 , Edited by admin on Fri Dec 15 15:52:37 GMT 2023
|
PRIMARY | Merck Index | ||
|
CHEMBL902
Created by
admin on Fri Dec 15 15:52:37 GMT 2023 , Edited by admin on Fri Dec 15 15:52:37 GMT 2023
|
PRIMARY | |||
|
4278
Created by
admin on Fri Dec 15 15:52:37 GMT 2023 , Edited by admin on Fri Dec 15 15:52:37 GMT 2023
|
PRIMARY | RxNorm | ||
|
FAMOTIDINE
Created by
admin on Fri Dec 15 15:52:37 GMT 2023 , Edited by admin on Fri Dec 15 15:52:37 GMT 2023
|
PRIMARY | |||
|
1269200
Created by
admin on Fri Dec 15 15:52:37 GMT 2023 , Edited by admin on Fri Dec 15 15:52:37 GMT 2023
|
PRIMARY | |||
|
4975
Created by
admin on Fri Dec 15 15:52:37 GMT 2023 , Edited by admin on Fri Dec 15 15:52:37 GMT 2023
|
PRIMARY | |||
|
1129
Created by
admin on Fri Dec 15 15:52:37 GMT 2023 , Edited by admin on Fri Dec 15 15:52:37 GMT 2023
|
PRIMARY | |||
|
W-33
Created by
admin on Fri Dec 15 15:52:37 GMT 2023 , Edited by admin on Fri Dec 15 15:52:37 GMT 2023
|
PRIMARY | |||
|
3572
Created by
admin on Fri Dec 15 15:52:37 GMT 2023 , Edited by admin on Fri Dec 15 15:52:37 GMT 2023
|
PRIMARY | |||
|
C29045
Created by
admin on Fri Dec 15 15:52:37 GMT 2023 , Edited by admin on Fri Dec 15 15:52:37 GMT 2023
|
PRIMARY | |||
|
5QZO15J2Z8
Created by
admin on Fri Dec 15 15:52:37 GMT 2023 , Edited by admin on Fri Dec 15 15:52:37 GMT 2023
|
PRIMARY | |||
|
76824-35-6
Created by
admin on Fri Dec 15 15:52:37 GMT 2023 , Edited by admin on Fri Dec 15 15:52:37 GMT 2023
|
PRIMARY |
ACTIVE MOIETY
METABOLITE (PARENT)